CCL2 and breast cancer: Namely, increased CCL2 level in the tumor by doxorubicin treatment promotes CCR2 dependent monocyte recruitment [19], although the PyMT mammary tumors normally recruit monocytes/macrophages via CCR6 but not CCR2 [20,21] .